Results 71 to 80 of about 28,601 (275)
Clinical Pharmacology &Therapeutics, EarlyView.One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision ...
Catherine M. E. de Cuba +7 more
wiley +1 more source
Determinación de Levetiracetam en suero mediante HPLC-UV
, 2014 El Levetiracetam es un medicamento antiepiléptico derivado de la pirrolidona con un mecanismo de acción diferente a otros antiepilépticos, al unirse de forma específica a la proteína SV2A de la vesícula sináptica modulando su actividad.
Sarmiento, Luz Adriana
core +1 more source
Drug Testing and Analysis, EarlyView.An LC–MS/MS method was developed for the detection of 33 psychoactive medications in cerumen (earwax) and applied to the samples of 60 psychiatric inpatient volunteers. The findings highlighted the utility of cerumen as an innovative biospecimen in clinical toxicological analysis.
Dimitrios Phaedon Kevrekidis +5 more
wiley +1 more source
Efficacy of Levetiracetam Monotherapy in Childhood Epilepsy
, 2017 Objectives:Levetiracetam (LEV) is an antiepileptic drug approved particularly for treatment of focal seizures. The aim of this study was to investigate efficacy and tolerability of LEV monotherapy in pediatric patients.Methods:In the present study ...
Betül KILIÇ +2 more
core +1 more source
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
, 2007 We report the results of a prospective study of the efficacy and tolerability of levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison with controlled-release carbamazepine as first treatment in newly diagnosed epilepsy.
Brodie M. J. +6 more
core +2 more sources
Epileptic Disorders, EarlyView.Abstract Background and Objectives Muscle‐Eye‐Brain disease (MEB) is a dystroglycanopathy that belongs to the congenital muscular dystrophies. Central nervous system manifestations include congenital brain abnormalities, neurodevelopmental delay, and epilepsy, making it a rare but important cause of developmental and epileptic encephalopathy.
Stefania Kalampokini +6 more
wiley +1 more source
, 2007 Epilepsy affects approximately 1% of the world population and is the most serious neurological conditions. In the UK, 30-35,000 new cases of epilepsy are diagnosed each year, resulting in a prevalence of 300,000 nationwide.
Tong, X.
core
, 2011 Levetiracetam is an effective anti-epileptic drug in the treatment of partial and generalized seizure. The purpose of the present study was to investigate whether levetiracetam regulates AMPA and NMDA receptor- mediated excitatory synaptic transmission ...
李君曜;陳至全;劉宏輝 +1 more
core
, 2009 In a newly described _Drosophila_ model, two of the five antiepileptic drugs (AEDs) tested, sodium valproate (NaVP) and levetiracetam (LEV), not ethosuximide (ETH), gabapentin (GBP) and vigabatrin (VGB), ameliorate development of chronic ...
Farhan Mohammad +2 more
core
A guide to neuromodulation in drug‐resistant epilepsy
Epileptic Disorders, EarlyView.Abstract Neuromodulation is approved for the treatment of drug‐resistant epilepsy. It has been increasingly utilized over the past two decades with the approval of deep brain stimulation (DBS) and responsive neurostimulation (RNS) in addition to vagus nerve stimulation (VNS)—particularly in patients who are not deemed to be good resective surgical ...
Prachi Parikh +10 more
wiley +1 more source